Hepatorenal Syndrome: Pathophysiology

Clin Liver Dis. 2022 May;26(2):165-179. doi: 10.1016/j.cld.2022.01.013. Epub 2022 Mar 30.

Abstract

Hepatorenal syndrome (HRS) is defined as a functional renal failure without major histologic changes in individuals with severe liver disease and it is associated with a high mortality rate. Renal hypoperfusion due to marked vasoconstriction as a result of complex circulatory dysfunction has been suggested to be the cornerstone of HRS. Splanchnic and peripheral arterial vasodilation and cirrhotic cardiomyopathy result in effective arterial hypovolemia and compensatory activation of vasoconstrictor mechanisms. The efficacy of current therapeutic strategies targeting this circulatory dysfunction is limited. Increasing evidence suggests a substantial role of systemic inflammation in HRS via either vascular or direct renal effects. Here we summarize the current understanding of HRS pathophysiology.

Keywords: Hepatorenal syndrome; Kidneys; Mortality; Pathophysiology; Systemic inflammation.

Publication types

  • Review

MeSH terms

  • Female
  • Hepatorenal Syndrome* / etiology
  • Hepatorenal Syndrome* / therapy
  • Humans
  • Liver Cirrhosis / complications
  • Male
  • Vasoconstrictor Agents / pharmacology
  • Vasoconstrictor Agents / therapeutic use
  • Vasodilation / physiology

Substances

  • Vasoconstrictor Agents